L. Stolz

发表

Identification and characterization of an essential family of inositol polyphosphate 5-phosphatases (INP51, INP52 and INP53 gene products) in the yeast Saccharomyces cerevisiae.

C. Huynh, J. Thorner, J. York, 1998, Genetics.

SAC1-like Domains of Yeast SAC1,INP52, and INP53 and of Human Synaptojanin Encode Polyphosphoinositide Phosphatases*

J. York, Shuling Guo, S. M. Lemrow, 1999, The Journal of Biological Chemistry.

Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.

J. Biedenkapp, J. Bernstein, W. Lumry, 2015, The journal of allergy and clinical immunology. In practice.

Hybridization of biotinylated oligo(dT) for Eukaryotic mRNA quantitation

R. Tuan, L. Stolz, 1996, Molecular biotechnology.

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.

J. Bernstein, W. Lumry, T. Craig, 2013, Allergy and asthma proceedings.

Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema

A. Sheffer, L. Stolz, 2012, Expert review of clinical immunology.

Administration of myostatin does not alter fat mass in adult mice

L. Klaman, J. Tobin, A. Qadri, 2006, Diabetes, obesity & metabolism.

Identification and Characterization of an Essential Family of Inositol Polyphosphate 5-Phosphatases ( INP 51 , INP 52 and INP 53 Gene Products ) in the Yeast Saccharomyces cerevisiae

C. Huynh, J. Thorner, J. York, 1998 .

Use of Ecallantide in Pediatric Hereditary Angioedema

R. Tachdjian, M. Davis-Lorton, A. MacGinnitie, 2013, Pediatrics.

Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency

A. Sheffer, A. Bousvaros, E. Rubinstein, 2014, BMC Gastroenterology.

Myostatin mutation associated with gross muscle hypertrophy in a child.

T. Braun, M. Schuelke, C. Hübner, 2004, The New England journal of medicine.

Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms

L. Klaman, M. Tam, Yan-ling Zhang, 2005, Molecular Pharmacology.

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates

Nicole M. Gaudelli, Christopher J. Cheng, K. G. Rajeev, 2021, Nature.

A phase 1 study investigating DX-2930 in healthy subjects.

J. Biedenkapp, D. Sexton, B. Vince, 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.

A. Sheffer, M. Campion, W. Pullman, 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.

M. Campion, W. Pullman, A. MacGinnitie, 2012, Allergy and asthma proceedings.

Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.

P. Horn, L. Stolz, 2010, Drugs of today.

Specificity Determinants in Phosphoinositide Dephosphorylation Crystal Structure of an Archetypal Inositol Polyphosphate 5-Phosphatase

James H. Hurley, Shuling Guo, John D. York, 2001, Cell.

Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses

L. Pearce, A. Bitonti, J. Andersen, 2019, Science Advances.

An expanded view of inositol signaling.

J. York, S. Guo, L. Stolz, 2001, Advances in enzyme regulation.

INP51, a Yeast Inositol Polyphosphate 5-Phosphatase Required for Phosphatidylinositol 4,5-Bisphosphate Homeostasis and Whose Absence Confers a Cold-resistant Phenotype*

J. York, M. Sekhon, J D York, 1998, The Journal of Biological Chemistry.

Off-label use: an industry perspective on expanding use beyond approved indications.

S. Mascioli, M. Russell, M. Friedman, 2006, Journal of interventional cardiology.